European Medicines Agency must take account of cardiovascular harm associated with degludec insulin

Thomas A Schmidt; Clifford J Rosen; John S Yudkin

doi:10.1136/bmj.f3731

European Medicines Agency must take account of cardiovascular harm associated with degludec insulin

Thomas A Schmidt, Clifford J Rosen, John S Yudkin

Department of Clinical Medicine

5 Citations (Scopus)

Original language	English
Journal	B M J
Volume	346
Pages (from-to)	f3731
ISSN	0959-8146
DOIs	https://doi.org/10.1136/bmj.f3731
Publication status	Published - 20 Jun 2013

Keywords

Cardiovascular Diseases
Diabetes Mellitus, Type 2
Drug Approval
Europe
European Union
Female
Government Agencies
Humans
Hypoglycemic Agents
Insulin, Long-Acting
Male
Product Surveillance, Postmarketing
Public Health
United States
United States Food and Drug Administration

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmj.f3731

Cite this

@article{3b333ce769454b0d926aea3d132c2088,

title = "European Medicines Agency must take account of cardiovascular harm associated with degludec insulin",

keywords = "Cardiovascular Diseases, Diabetes Mellitus, Type 2, Drug Approval, Europe, European Union, Female, Government Agencies, Humans, Hypoglycemic Agents, Insulin, Long-Acting, Male, Product Surveillance, Postmarketing, Public Health, United States, United States Food and Drug Administration",

author = "Schmidt, {Thomas A} and Rosen, {Clifford J} and Yudkin, {John S}",

year = "2013",

month = jun,

day = "20",

doi = "10.1136/bmj.f3731",

language = "English",

volume = "346",

pages = "f3731",

journal = "The BMJ",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - European Medicines Agency must take account of cardiovascular harm associated with degludec insulin

AU - Schmidt, Thomas A

AU - Rosen, Clifford J

AU - Yudkin, John S

PY - 2013/6/20

Y1 - 2013/6/20

KW - Cardiovascular Diseases

KW - Diabetes Mellitus, Type 2

KW - Drug Approval

KW - Europe

KW - European Union

KW - Female

KW - Government Agencies

KW - Humans

KW - Hypoglycemic Agents

KW - Insulin, Long-Acting

KW - Male

KW - Product Surveillance, Postmarketing

KW - Public Health

KW - United States

KW - United States Food and Drug Administration

U2 - 10.1136/bmj.f3731

DO - 10.1136/bmj.f3731

M3 - Journal article

C2 - 23757746

SN - 0959-8146

VL - 346

SP - f3731

JO - The BMJ

JF - The BMJ

ER -